Document:

EX-4.6

 Exhibit 4.6 

Execution Version 

REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 16, 2016 by and
between EOG Resources, Inc., a Delaware corporation (“Parent”), and Yates Industries, LLC, a New Mexico limited liability company (the “Stockholder”). 

RECITALS 
 WHEREAS, this
Agreement is made in connection with (1) the closing of the transactions contemplated by the Asset Purchase and Sale Agreement (the “Purchase Agreement”), dated as of September 2, 2016, by and among Parent, EOG
Resources Assets LLC, a Delaware limited liability company, and the Stockholder, and (2) the issuance of the Subject Common Stock on the Closing Date pursuant to the Purchase Agreement; and 

WHEREAS, Parent has agreed to provide the registration and other rights set forth in this Agreement, subject to Parent’s receipt of a
complete Selling Stockholder Questionnaire from the Stockholder, in the form attached hereto as Annex A (the “Questionnaire”), by November 18, 2016, for the benefit of the Stockholder, who received Subject Common
Stock on the Closing Date as Stock Consideration. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth
herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each party hereto, the parties hereby agree as follows: 

ARTICLE I 

REGISTRATION RIGHTS 

Section 1.01 Shelf Registration. 

(a) Shelf Registration. Subject to the delivery of the Questionnaire as contemplated by the Recitals, Parent shall
(i) prepare and file a registration statement under the Securities Act to permit the public resale of the Registrable Securities from time to time, including as permitted by Rule 415 under the Securities Act (or any similar provision then
in force), with respect to all of the Registrable Securities (the “Shelf Registration Statement”) and (ii) cause such Shelf Registration Statement to become effective as soon as reasonably practicable thereafter but in
no event later than December 3, 2016 (the “Effectiveness Deadline”). The Shelf Registration Statement filed pursuant to this Section 1.01(a) shall be on
Form S-3 of the SEC if Parent is eligible to use Form S-3 or Form S-1 of the SEC if Parent is not eligible to use Form S-3. Subject to Section 1.01(b), Parent will cause the Shelf Registration Statement filed pursuant to this Section 1.01(a) to be continuously effective
under the Securities Act from and after the date it is first declared or becomes effective until all Registrable Securities covered by the Shelf Registration Statement have been distributed in the manner set forth and as contemplated in the Shelf
Registration Statement or there are no longer any Registrable Securities outstanding (the “Effectiveness Period”). The Shelf Registration Statement when declared effective (including the documents incorporated therein by
reference) shall comply as to form with all applicable requirements of the Securities Act and the Exchange Act and shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading. As soon as practicable following the beginning of the Effectiveness Period, but in any event within three Business Days of such date, Parent will notify the Selling Holders of the effectiveness of such
Shelf Registration Statement. 

 (b) Delay Rights. Notwithstanding anything to the contrary contained
herein, Parent may, upon written notice to any Selling Holder whose Registrable Securities are included in the Shelf Registration Statement, suspend such Selling Holder’s use of any prospectus which is a part of the Shelf Registration
Statement (in which event the Selling Holder shall discontinue sales of the Registrable Securities pursuant to the Shelf Registration Statement but such Selling Holder may settle any contracted sales of Registrable Securities) if Parent
(i) is pursuing an acquisition, merger, reorganization, disposition or other similar transaction that Parent reasonably believes would be required by applicable law to be disclosed in the Shelf Registration Statement and the Board of Directors
of Parent (the “Parent Board”) determines in good faith that its ability to pursue or consummate such a transaction would be materially and adversely affected by any required disclosure of such transaction in
the Shelf Registration Statement or (ii) has experienced some other material non-public event the disclosure of which at such time, in the good faith judgment of the Parent Board would materially and
adversely affect Parent; provided, however, in no event shall such Selling Holders be suspended under clauses (i) or (ii) of this Section 1.01(b) from selling
Registrable Securities pursuant to the Shelf Registration Statement for a period that exceeds 30 consecutive days or 45 days in the aggregate. Upon disclosure of such information or the termination of the condition described above, Parent shall
provide prompt notice to the Selling Holders whose Registrable Securities are included in the Shelf Registration Statement, and shall promptly terminate any suspension of sales it has put into effect and shall take such other actions to permit
registered sales of Registrable Securities as contemplated in this Agreement. 
 Section 1.02 Registration Procedures. 

(a) In connection with its obligations under this Article I, Parent will, as expeditiously as
possible: 
 (i) prepare and file with the SEC such amendments and supplements to the Shelf Registration Statement and the
prospectus used in connection therewith as may be necessary to cause the Shelf Registration Statement to be effective and to keep the Shelf Registration Statement effective for the Effectiveness Period and as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all securities covered by the Shelf Registration Statement; 

(ii) furnish to each Selling Holder and each Selling Holder’s representatives and counsel designated in writing by such
Selling Holder to Parent (A) as far in advance as reasonably practicable before filing the Shelf Registration Statement or any amendment or supplement thereto a copy of a reasonably complete draft of such Shelf Registration Statement or any
amendment or supplement thereto, and provide each such Selling Holder the opportunity to object to any information pertaining to such Selling Holder and its plan of distribution that is contained therein and make the corrections reasonably requested
by such Selling Holder with respect to such information prior to filing the Shelf Registration Statement or any amendment or supplement thereto, and (B) a copy of the filed Shelf Registration Statement or any amendment or supplement thereto;

 (iii) promptly notify each Selling Holder, at any time when (A) a prospectus relating thereto is required to be
delivered under the Securities Act, of the filing of the Shelf Registration Statement or any amendment or supplement thereto, and, when the same has become effective, (B) the receipt of any written comments from the SEC with respect to any
filings referred to in clause (A) and any written request by the SEC for 

  
 2 

 
amendments or supplements to a Shelf Registration Statement, or (C) copies of any and all transmittal letters or other correspondence filed via EDGAR with the SEC or any other Governmental
Authority relating to a Shelf Registration Statement (it being understood that each Selling Holder receiving any materials from Parent contemplated herein shall (and shall cause its representatives and counsel to) keep such materials confidential);
and 
 (iv) immediately notify each Selling Holder, each Selling Holder’s representatives and counsel, and each
underwriter of Registrable Securities, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of (A) the happening of any event as a result of which the prospectus or prospectus supplement contained
in the Shelf Registration Statement or any other registration statement contemplated by this Agreement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary
to make the statements therein not misleading, in the light of the circumstances then existing; (B) the issuance or threat of issuance by the SEC of any stop order suspending the effectiveness of the Shelf Registration Statement or any other
registration statement contemplated by this Agreement, or the initiation of any Proceedings for that purpose; or (C) the receipt by Parent of any notification with respect to the suspension of the qualification of any Registrable Securities for
sale under the applicable securities or “Blue Sky” laws of any jurisdiction. Following the provision of such notice, Parent agrees to as promptly as practicable amend or supplement the prospectus or prospectus supplement or take other
appropriate action so that the prospectus or prospectus supplement does not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, in
the light of the circumstances then existing, and to take such other action as is necessary to remove a stop order, suspension, threat thereof or Proceedings related thereto. 

(b) Each Selling Holder, upon receipt of notice from Parent of the happening of any event of the kind described in
Section 1.02(a)(iv), shall forthwith discontinue disposition of the Registrable Securities until it is advised in writing by Parent that the use of the prospectus may be resumed. Parent shall extend the period of time
during which Parent is required to maintain the Shelf Registration Statement effective pursuant to this Agreement by the number of days during the period from and including the date of the giving of notice from Parent pursuant to
Section 1.02(a)(iv) to and including the date the Selling Holder is advised in writing by Parent that the use of the prospectus may be resumed. 

Section 1.03 Registrable Securities. Any Registrable Security will cease to be a Registrable Security when (a) a registration
statement covering such Registrable Security is effective and such Registrable Security has been sold or disposed of pursuant to such effective registration statement; (b) such Registrable Security has been disposed of pursuant to any section
of Rule 144; or (c) such security becomes eligible for sale pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement
for Parent to be in compliance with the current public information requirement under Rule 144(c)(1). 
 Section 1.04 Lack of
Required Information. Parent shall have no obligation to include in the Shelf Registration Statement any shares of Subject Common Stock of a Holder who has failed to timely furnish such information which, in the opinion of counsel to
Parent, is reasonably required to be furnished or confirmed in order for the registration statement or prospectus supplement thereto, as applicable, to comply with the Securities Act. 

  
 3 

 Section 1.05 Disclosure of Information. If the Stockholder desires to have its
Registrable Securities included in the Shelf Registration Statement it shall provide to Parent all information required to be disclosed therein. Except to the extent such information is disclosed in the Shelf Registration Statement, Parent shall
(and shall cause its agents and representatives to) hold all such information in confidence and not make any disclosure thereof unless (a) the disclosure of such information is necessary to comply with federal or state securities laws,
(b) the disclosure of such information is necessary to avoid or correct an untrue statement of a material fact required to be stated in the Shelf Registration Statement, (c) the release of such information is ordered pursuant to a subpoena
or other final, non-appealable order from a Governmental Authority of competent jurisdiction, or (d) such information has been made generally available to the public other than by disclosure in violation
of this Agreement or any other agreement. Parent agrees that it shall, upon learning that disclosure of any such information (other than that disclosed in the Shelf Registration Statement) is sought in or by a Governmental Authority of competent
jurisdiction or through other means, give prompt written notice to the Stockholder and allow the Stockholder to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information. 

Section 1.06 Expenses. Parent will pay all expenses incident to Parent’s performance under or compliance with this Agreement
to effect the registration of Registrable Securities on the Shelf Registration Statement, including, without limitation, all registration, filing, securities exchange listing fees, all customary registration, filing, qualification and other fees and
expenses of complying with securities or “Blue Sky” laws, fees of transfer agents and registrars, all word processing, duplicating and printing expenses, and the fees and disbursements of counsel and independent public accountants and
independent reserve engineers for Parent. Notwithstanding the foregoing, “registration expenses” described in this Section 1.06 shall exclude all selling commissions and similar fees and fees of counsel incurred
by the Stockholder in connection with the sale of any Registrable Securities. 
 Section 1.07 [Intentionally Omitted.] 

Section 1.08 Indemnification. 

(a) By Parent. In the event of a registration of any Registrable Securities under the Securities Act pursuant to
this Agreement, Parent will indemnify and hold harmless each Selling Holder thereunder, its Affiliates that own Registrable Securities and their respective directors, officers, managers, members, partners, stockholders, Affiliates or any other
Person acting on behalf of such holder of Registrable Securities and each Person, if any, who controls such Selling Holder within the meaning of the Securities Act and the Exchange Act and its directors, officers, managers, members, partners,
stockholders, Affiliates or any other Person acting on behalf of such holder of Registrable Securities (collectively, the “Selling Holder Indemnified Persons”), against any losses, claims, damages, expenses or
liabilities (including reasonable attorneys’, accountants’ and experts’ fees and expenses) (collectively, “Losses”), joint or several, to which such Selling Holder or controlling Person may become subject under
the Securities Act, the Exchange Act or otherwise, insofar as such Losses (or Proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact
contained in the Shelf Registration Statement or any other registration statement contemplated by this Agreement, any prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, in light of the circumstances under which they were made) not misleading, in connection with the
registration statement in respect of any registration of Parent’s securities, and will reimburse each such Selling Holder Indemnified Person for any legal or other expenses reasonably incurred by them in connection with

  
 4 

 
investigating or defending any such Loss or Proceedings; provided, however, that Parent will not be liable in any such case if and to the extent that any such Loss arises out of or
is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Selling Holder Indemnified Person in writing specifically for use in the Shelf Registration
Statement or such other registration statement or any prospectus (including, if applicable, any preliminary or free writing prospectus) contained therein or any amendment or supplement thereof. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such Selling Holder or any such director, officer or controlling Person, and shall survive the transfer of such securities by such Selling Holder. 

(b) By Each Selling Holder. Each Selling Holder agrees severally and not jointly to indemnify and hold harmless
Parent, its directors and officers, and each Person, if any, who controls Parent within the meaning of the Securities Act or of the Exchange Act against any Losses to the same extent as the foregoing indemnity from Parent to the Selling Holders, but
only with respect to information regarding such Selling Holder furnished in writing by or on behalf of such Selling Holder expressly for inclusion in the Shelf Registration Statement or any prospectus (including, if applicable, any preliminary or
free writing prospectus) contained therein or any amendment or supplement thereof relating to the Registrable Securities; provided, however, that the liability of each Selling Holder shall not be greater in amount than the dollar
amount of the proceeds received by such Selling Holder from the sale of the Registrable Securities giving rise to such indemnification. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of
Parent or any such director, officer or controlling Person, and shall survive the transfer of such securities by such Selling Holder. 

(c) Notice. Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action,
such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but such indemnified party’s failure to so notify the indemnifying party shall
not relieve the indemnifying party from any liability which it may have to any indemnified party other than under this Section 1.07. The indemnifying party shall be entitled to participate in and, to the extent it shall
wish, to assume and undertake the defense thereof with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof,
the indemnifying party shall not be liable to such indemnified party under this Section 1.07 for any legal expenses subsequently incurred by such indemnified party in connection with the defense thereof other than
reasonable costs of investigation and of liaison with counsel so selected; provided, however, that, (i) if the indemnifying party has failed to assume the defense and employ counsel reasonably acceptable to the indemnified party
or (ii) if the defendants in any such action include both the indemnified party and the indemnifying party and counsel to the indemnified party shall have concluded that there may be reasonable defenses available to the indemnified party that
are different from or additional to those available to the indemnifying party, or if the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, then the indemnified party shall have the
right to select a separate counsel and to assume such legal defense and otherwise to participate in the defense of such action, with the reasonable expenses and fees of one such separate counsel (firm) and other reasonable expenses related to
such participation to be reimbursed by the indemnifying party as incurred. Notwithstanding any other provision of this Agreement, no indemnified party shall settle any action brought against it with respect to which it is entitled to indemnification
hereunder without the consent of the indemnifying party, unless the settlement thereof imposes no liability or obligation on, and includes a complete and unconditional release from all liability of, the indemnifying party. 

  
 5 

 (d) Contribution. If the indemnification provided for in this
Section 1.07 is held by a Governmental Authority of competent jurisdiction to be unavailable to Parent or any Selling Holder Indemnified Person or is insufficient to hold it harmless in respect of any Losses, then each such
indemnifying party, in lieu of indemnifying such indemnified party, shall contribute the amount paid or payable by such indemnified party as a result of such Losses as between Parent, on the one hand, and such Selling Holder Indemnified Person, on
the other hand, in such proportion as is appropriate to reflect the relative fault of Parent, on the one hand, and of such Selling Holder Indemnified Person, on the other, in connection with the statements or omissions which resulted in such Losses,
as well as any other relevant equitable considerations; provided, however, that in no event shall such Selling Holder Indemnified Person be required to contribute an aggregate amount in excess of the dollar amount of proceeds received
by such Selling Holder Indemnified Person from the sale of Registrable Securities giving rise to such indemnification. The relative fault of Parent, on the one hand, and each Selling Holder Indemnified Person, on the other hand, shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact has been made by, or relates to, information supplied by such party, and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contributions pursuant to this paragraph were to be
determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the first sentence of this paragraph. The amount paid by an indemnifying party as a result of the
Losses referred to in the first sentence of this paragraph shall be deemed to include any legal and other expenses reasonably incurred by such indemnified party in connection with investigating or defending any Loss which is the subject of this
paragraph. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who is not guilty of such fraudulent misrepresentation. 

(e) Other Indemnification. The provisions of this Section 1.07 shall be in addition to
any other rights to indemnification or contribution which an indemnified party may have pursuant to law, equity, contract or otherwise. 

Section 1.09 Rule 144 Reporting. With a view to making available the benefits of certain rules and
regulations of the SEC that may permit the sale of the Registrable Securities to the public without registration, Parent agrees to use its reasonable best efforts to: 

(a) make and keep public information regarding Parent available, as those terms are understood and defined in Rule 144, at
all times from and after the Closing Date; 
 (b) file with the SEC in a timely manner all reports and other documents
required of Parent under the Securities Act and the Exchange Act at all times from and after the Closing Date; and 
 (c)
take such further action as any Holder may reasonably request, all to the extent required from time to time to enable the Holders to sell Registrable Securities without registration under the Securities Act within the limitations of the exemption
provided by Rule 144. 
 Section 1.10 Regulation M. Parent will not take any direct or indirect action prohibited by
Regulation M under the Exchange Act. 

  
 6 

 Section 1.11 Cooperation. Parent shall cooperate with the holders of the Registrable
Securities to facilitate the timely preparation and delivery of certificates representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of
shares of Common Stock as the holders of the Registrable Securities may reasonably request in connection with any sales of Registrable Securities pursuant to such Registration Statement or Rule 144; provided, that Parent may satisfy its
obligations hereunder without issuing physical stock certificates. 
 Section 1.12 No Transfer or Assignment. Except with
respect to a transferee pursuant to a transfer permitted under Section 1.14(c), the rights to cause Parent to include Registrable Securities in a Shelf Registration Statement may not be transferred or assigned by the
Stockholder. 
 Section 1.13 Requested Information. Any Holder or Holders of Registrable Securities included in any registration
statement shall promptly furnish to Parent such information regarding such Holder or Holders and the distribution or transfer proposed by such Holder or Holders as Parent may reasonably request and as shall be required in connection with any
registration, qualification or compliance referred to herein. 
 Section 1.14 Graduated
Lock-up. 
 (a) 100% Lock-up Period
(commencing on the Closing Date-December 3, 2016). Subject to Section 1.14(c), notwithstanding the filing and effectiveness of the Shelf Registration Statement, each Holder hereby agrees that it will not (and will
cause its Affiliates not to), without the prior written consent of Parent, during the period commencing on the Closing Date and ending immediately before the commencement of trading on December 4, 2016 (or, if such calendar day is not a trading
day, then the immediately succeeding trading day) (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any shares of Subject Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Subject Common Stock (whether such shares or any such securities are
then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction
described in clause (i) or (ii) above is to be settled by delivery of Subject Common Stock or other securities, in cash, or otherwise. 

(b) 50% Lock-up Period (December 4, 2016-February 1, 2017).
Subject to Section 1.14(c), each Holder hereby agrees that it will not (and will cause its Affiliates not to), without the prior written consent of Parent, during the period commencing at the commencement of trading
on December 4, 2016 (or, if such calendar day is not a trading day, then the immediately succeeding trading day) and ending immediately before the commencement of trading on February 2, 2017 (or, if such calendar day is not a trading day,
then the immediately succeeding trading day), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, more than 50% of the shares of Subject Common Stock received by such Holder as Stock Consideration pursuant to the Purchase Agreement or (ii) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of
Subject Common Stock or other securities, in cash, or otherwise. 

  
 7 

 (c) Nothing in this Section 1.14 shall prohibit or
limit the ability of any Holder to effect any transfer of shares of Subject Common Stock as a bona fide gift or gifts or any other similar transfer that does not involve a sale or other disposition for value so long as the transferee agrees in
writing to be bound by all of the terms of this Agreement. 
 ARTICLE II 

TERMINATION 

Section 2.01 Termination. This Agreement may be completely terminated at any time at or prior to November 18, 2016 by Parent
if the Stockholder has not delivered a complete Questionnaire to Parent by November 18, 2016. 
 Section 2.02 Effect of
Termination. In the event that a complete Questionnaire is not delivered to Parent by November 18, 2016, then except as set forth in Article III, this Agreement shall terminate and be null and void. 

ARTICLE III 

MISCELLANEOUS 

Section 3.01 Definitions. Capitalized terms used herein without definition shall have the meanings given to them in the Purchase
Agreement, except that the terms set forth below are used herein as so defined: 
 “Common Stock” means shares of
Parent’s common stock, par value $0.01 per share. 
 “Holder” means a holder of any Registrable Securities.

 “Registrable Security” means a share of Subject Common Stock until such time as such security ceases to be a
Registrable Security pursuant to Section 1.03 hereof. 
 “Rule 144” means Rule 144 under
the Securities Act or any successor rule thereto. 
 “SEC” means the U.S. Securities and Exchange Commission.

 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Selling Holder” means a Holder who is selling Registrable Securities pursuant to a registration
statement. 
 “Subject Common Stock” means Common Stock issued to the Stockholder pursuant to the Purchase
Agreement. 
 Section 3.02 Communications. All notices and other communications provided for hereunder shall be in writing and
shall be given by hand delivery, registered or certified mail, return receipt requested, regular mail, facsimile or air courier guaranteeing overnight delivery to the following addresses: 

if to Parent to: 

EOG Resources, Inc. 

1111 Bagby, Sky Lobby 2 

  
 8 

 Houston, Texas 77002 

Attention: Lloyd W. Helms, Jr., Executive Vice President, Exploration and Production 

Fax: (713) 651-6987 

Email: Billy_Helms@eogresources.com 

and 

EOG Resources, Inc. 

1111 Bagby, Sky Lobby 2 

Houston, Texas 77002 

Attention: Michael P. Donaldson, Exec. VP and General Counsel 

Fax: (713) 651-6987 

Email: Michael_Donaldson@eogresources.com 

with a copy (which shall not constitute notice) to: 

Akin Gump Strauss Hauer & Feld, LLP 

1111 Louisiana Street, 44th Floor 

Houston, Texas 77002 

Attention: John Goodgame, Andrew B. Lehman 

Fax: (713) 236-0822 

Email: jgoodgame@akingump.com, alehman@akingump.com 

if to the Stockholder to: 

Yates Industries, LLC 

403 West San Francisco 

Santa Fe, New Mexico 87505 

Attention: Frank Yates, Jr. 

Fax No.: (505) 982-4581 

E-mail: frank.yates@deskoptional.com 

with a copy (which shall not constitute notice) to: 

Pillsbury Winthrop Shaw Pittman LLP 

401 Congress Avenue, Suite 1700 

Austin, TX 78701-3797 

Attention: Dillon J. Ferguson 

Fax No.: (512) 580-9601 

E-mail: dillon.ferguson@pillsburylaw.com 

or to such other address or addresses as the parties may from time to time designate in writing. 

All notices and communications shall be deemed to have been duly given: (i) at the time delivered by hand, if personally delivered; (ii) upon actual
receipt if sent by registered or certified mail, return receipt requested, or regular mail, if mailed; (iii) upon actual receipt if received during recipient’s normal business hours, or at the beginning of the recipient’s next
Business Day if not received during recipient’s normal business hours, if sent by facsimile and confirmed by appropriate answer-back; and (iv) upon actual receipt when delivered to an air courier guaranteeing overnight delivery. 

  
 9 

 Section 3.03 Successors and Assigns. This Agreement shall inure to the benefit of and
be binding upon the permitted successors and assigns of each of the parties. 
 Section 3.04 Recapitalization, Exchanges, etc.
Affecting the Common Stock. The provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all common stock of Parent or any successor or assign of Parent (whether by merger, consolidation, sale of
assets or otherwise) which may be issued in respect of, in exchange for or in substitution of, the Registrable Securities, and shall be appropriately adjusted for combinations, recapitalizations and the like occurring after the date of this
Agreement. 
 Section 3.05 Specific Performance. Damages in the event of breach of this Agreement by a party hereto may be
difficult, if not impossible, to ascertain, and it is therefore agreed that each such Person, in addition to and without limiting any other remedy or right it may have, will have the right to an injunction or other equitable relief in any court of
competent jurisdiction, enjoining any such breach, and enforcing specifically the terms and provisions hereof, and each of the parties hereto hereby waives any and all defenses it may have on the ground of lack of jurisdiction or competence of the
court to grant such an injunction or other equitable relief. The existence of this right will not preclude any such Person from pursuing any other rights and remedies at law or in equity which such Person may have. 

Section 3.06 Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in
separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same Agreement. 

Section 3.07 Interpretation. When a reference is made in this Agreement to an Article, a Section, Exhibit or Schedule, such
reference shall be to an Article of, a Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words
“hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All terms defined in this
Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such
agreement, instrument or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and
references to all attachments thereto and instruments incorporated therein. References to a Person are also to its permitted successors and permitted assigns. Unless specifically provided for herein, the term “or” shall not be deemed to be
exclusive. The word “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase shall not mean simply “if”. The words “will” and “will not” are
expressions of command and not merely expressions of future intent or expectation. When used in this Agreement, the word “either” shall be deemed to mean “one or the other”, not “both”. All references herein to
“dollars” or “$” are to the lawful currency of the United States. 

  
 10 

 Section 3.08 Governing Law. This Agreement is governed by and construed and enforced
in accordance with the Laws of the State of Delaware, without giving effect to any conflicts of law principles that would result in the application of any Law other than the Law of the State of Delaware. 

Section 3.09 WAIVER OF JURY TRIAL. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, EACH PARTY HEREBY
IRREVOCABLY WAIVES AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING IN WHOLE OR IN PART UNDER,
RELATED TO, BASED ON, OR IN CONNECTION WITH, THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER SOUNDING IN TORT OR CONTRACT OR OTHERWISE. ANY PARTY MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS
SECTION 3.09 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

Section 3.10 Severability of Provisions. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof or affecting or impairing the validity or enforceability of such provision in any other
jurisdiction. 
 Section 3.11 Entire Agreement. This Agreement is intended by the parties as a final expression of their
agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. There are no restrictions, promises, warranties or undertakings, other than
those set forth or referred to herein with respect to the rights granted by Parent set forth herein. This Agreement and the Purchase Agreement supersede all prior agreements and understandings between the parties with respect to such subject matter.

 Section 3.12 Amendment. This Agreement may be amended only by means of a written amendment signed by Parent and the
Stockholder. 
 Section 3.13 No Presumption. In the event any claim is made by a party relating to any conflict, omission, or
ambiguity in this Agreement, no presumption or burden of proof or persuasion shall be implied by virtue of the fact that this Agreement was prepared by or at the request of a particular party or its counsel. 

Section 3.14 Further Assurances. Parent and each of the Holders shall cooperate with each other and shall take such further action
and shall execute and deliver such further documents as may be reasonably requested by any other party in order to carry out the provisions and purposes of this Agreement. 

[Signature page follows.] 

  
 11 

 IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of the date
and year first written above. 
  

			
	PARENT:
	
	EOG RESOURCES, INC.
		
	By:	 	 /s/ Michael P. Donaldson

	Name:	 	Michael P. Donaldson
	Title:	 	Executive Vice President, General Counsel and Corporate Secretary

 Signature Page to 

Registration Rights Agreement 

 
			
	STOCKHOLDER:
	
	YATES INDUSTRIES, LLC
		
	By:	 	 /s/ Frank Yates, Jr.

	Name:	 	Frank Yates, Jr.
	Title:	 	Manager

 Signature Page to 

Registration Rights Agreement 

 ANNEX A 

QUESTIONNAIRE 

 EOG RESOURCES, INC. 

NOTICE AND SELLING STOCKHOLDER QUESTIONNAIRE 

Pursuant to that certain Registration Rights Agreement, dated November 16, 2016, by and between EOG Resources, Inc., a Delaware
corporation (the “Company”), and Yates Industries, LLC (the “Selling Stockholder”), the Company intends to file with the Securities and Exchange Commission (the “Commission”) a
registration statement (as amended or supplemented from time to time, the “Registration Statement”) on Form S-3 for the registration and resale under the Securities Act of 1933 (as
amended, the “Securities Act”), of shares of common stock (the “Registrable Securities”) received by the Selling Stockholder in connection with the Asset Purchase and Sale Agreement, dated as of
September 2, 2016, by and among the Company, EOG Resources Assets LLC, a Delaware limited liability company, and the Selling Stockholder. 

The Registration Statement is required so that you will be able to freely sell, at some point in the future, your Registrable Securities. The
purpose of this Notice and Selling Stockholder Questionnaire (the “Questionnaire”) is to provide the Company with information required to be disclosed in the Registration Statement by the rules and regulations of the
Commission. Although you are referred to in this Questionnaire as a “Selling Stockholder,” this does not mean that the Registration Statement will result in the resale of your Registrable Securities. You will still have to take other
actions in order to sell your Registrable Securities, and you will choose when to take those other actions. 
 Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and any related amendment or prospectus supplement. Accordingly, you are advised to consult your own securities law counsel regarding the consequences of being named or
not being named as a selling stockholder in the Registration Statement and any related amendment or prospectus supplement. 
 If you have
any questions regarding this Questionnaire, please contact Cynthia Angell 
 at 713-250-2245 or cangell@akingump.com. 
 Please fax or
e-mail a copy of the completed and executed Questionnaire by 

November 18, 2016 and return the original to: 

Akin Gump Strauss Hauer & Feld LLP 

1111 Louisiana Street, 44th Floor 

Houston, Texas 77002-5200 
 Attn:
Cynthia Angell 
 Telephone: (713) 250-2245 

Fax: (713) 236-0822 

Email: cangell@akingump.com 

 NOTICE 

The undersigned Selling Stockholder hereby elects to include the following shares of Registrable Securities registered in the name of the undersigned Selling
Stockholder in the Registration Statement: 
  

	☐	All of the undersigned’s shares of Registrable Securities 

	☐	Only
                                     (specify number) of the
undersigned’s shares of Registrable Securities 

 QUESTIONNAIRE 

Please answer every question. As used in this Questionnaire, “you” refers, as applicable, to you as an individual Selling Stockholder or to the
entity Selling Stockholder on behalf of which you are completing this Questionnaire. 
  

	1.	IDENTIFICATION INFORMATION 

  

							
	 (a)    
	 	If you are an Individual Selling Stockholder, please provide:	  	
				
		 	 Full Legal Name:
	  	  
	  	
				
		 	 Date of Birth:
	  	  
	  	
				
		 	 Home Address:
	  	  
	  	
				
		 		  	  
	  	
				
		 		  	  
	  	
				
		 	Telephone:	  	  
	  	
				
		 	E-mail:	  	  
	  	

  

							
	 (b)    
	 	If you are an Entity Selling Stockholder, please provide:	  	
				
		 	 Full Legal Name:
	  	  
	  	
			
		 	 State of Incorporation or Jurisdiction of Organization:
	  	
			
		 	  
	  	
				
		 	 Type of Entity:
	  	  
	  	
				
		 	 Address:
	  	  
	  	
				
		 		  	  
	  	
				
		 		  	  
	  	
				
		 	 Attention:
	  	  
	  	
				
		 	Telephone:	  	  
	  	
				
		 	E-mail:	  	  
	  	
			
		 	 Name and Position of Authorized Signatory:
	  	
			
		 	  
	  	

  
 1 

	2.	NATURE OF BENEFICIAL OWNERSHIP 

 The purpose of this question is to identify the “beneficial
owner” of the Registrable Securities. Please see Exhibit A for the definition of “beneficial owner.” 
  

					
	(a)  	  	The Selling Stockholder is (please check one):
			
		  	☐	  	a natural person
			
		  	☐	  	a company that is required to file, or is a wholly owned subsidiary of a company that is required to file, periodic and other reports (e.g., Forms 10-K,
10-Q, 8-K) with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act
			
		  		  	If a subsidiary, please identify the reporting company parent:
			
		  		  	  

			
		  	☐	  	a registered investment company, or a subsidiary of a registered investment company, under the Investment Company Act of 1940
			
		  		  	If a subsidiary, please identify the registered investment company parent:
			
		  		  	  

			
		  	☐	  	a non-profit charitable foundation under Section 501(c)(3) of the Internal Revenue Code
			
		  	☐	  	a corporation*
			
		  	☐	  	a limited liability company*
			
		  	☐	  	a general partnership*
			
		  	☐	  	a limited liability limited partnership or a limited partnership*
			
		  	☐	  	a trust*
			
		  	☐	  	other*                                     
                                         
                   (please specify)
		
		  	If you checked any of the items marked with an asterisk, please proceed to Question 2(b). Otherwise, you may skip to Question 3.
		
	(b)	  	Please (i) identify the full legal name and title of each natural person who, directly or indirectly through any contract, arrangement, understanding, relationship, or otherwise, exercises sole or shared voting
and/or investment control over the Registrable Securities and (ii) describe the relationship between such natural person(s) and the registered holder of the Registrable Securities (e.g., general partner-limited partnership,
trustee-trust).
		
		  	If the Selling Stockholder is managed or controlled by another entity instead of one or more natural persons, please proceed up the entity chain until you reach the one or more natural persons that exercise sole or
shared voting and/or investment control over the Registrable Securities.
		
		  	  

		
		  	  

		
		  	  

		
		  	  

		
		  	  

  
 2 

					
		
		  	If you need more space for this response, please attach additional sheets of paper. Please be sure to indicate your name and the number of the Question to which you are responding on each such additional sheet of
paper, and to sign each such additional sheet of paper before attaching it to this Questionnaire. Please note that you may be asked to answer additional questions depending on your response to these questions.

  

	3.	BROKER-DEALER STATUS 

  

			
	(a)	  	Are you a broker-dealer?

 Yes ☐        No ☐ 

If “Yes,” did you receive your Registrable Securities as compensation for investment banking services to the Company? 

Yes ☐        No ☐ 

 

			
		  	Note: If “No,” the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
		
	(b)	  	Are you an affiliate of a broker-dealer?

 Yes ☐        No ☐ 

 

			
		  	If “Yes,” please identify the broker-dealer and describe the relationship between you and the broker-dealer (i.e., employee-employer, husband-wife, etc.):
		
		  	  

		
		  	  

		
		  	If “Yes,” do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings,
directly or indirectly, with any person to distribute the Registrable Securities?

 Yes ☐        No ☐ 

 

			
		  	Note: If “No,” the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

  

	4.	ACQUISITION OF SHARES 

 Did you acquire the Registrable Securities directly from the
Company? 
 Yes ☐        No ☐ 

If “No,” please describe the manner in which the Registrable Securities were acquired including, the date, the name and address of
the seller(s), the purchase price and the transaction documents and please forward such documents to the contact person at the e-mail address or mailing address indicated on the cover of this Questionnaire.

  
 3 

			
		
		  	  

		
		  	  

		
		  	  

  

	5.	OWNERSHIP OF SECURITIES OF THE COMPANY 

 Are you the beneficial or registered owner of
any securities of the Company other than the Registrable Securities? Please see Exhibit A for the definition of “beneficial owner.” 

Yes ☐        No ☐ 

If “Yes,” please describe the type and amount of securities of the Company other than the Registrable Securities that you
beneficially own or for which you are the registered holder: 
  

			
		
		  	  

		
		  	  

 [Item 507 of Regulation S-K] 

 

	6.	RELATIONSHIPS WITH THE COMPANY 

 Have you or, if applicable, any of your affiliates,
officers, directors or principal equity holders (owners of 5% of your equity securities) held any position or office or had any other material relationship with the Company (or its predecessors or affiliates) during the past three years? 

Yes ☐        No ☐ 

If “Yes,” please describe the relationship: 
  

			
		
		  	  

		
		  	  

 [Item 507 of Regulation S-K] 

 

	7.	LEGAL PROCEEDINGS WITH THE COMPANY 

 Are you or, if applicable, any of your affiliates,
officers, directors or principal equity holders (owners of 5% of more of your equity securities) party to any pending legal proceeding in which the Company (or its predecessors or affiliates) is named as an adverse party? 

Yes ☐        No ☐ 

If “Yes,” please describe the proceedings: 

			
		
		  	  

		
		  	  

  
 4 

 SIGNATURE 

By signing below, the undersigned: 
  

	 	•	 	represents that the information provided in this Questionnaire is accurate and complete; 

  

	 	•	 	acknowledges and agrees that the certifications, representations, warranties and agreements contained in this Questionnaire are made for the benefit of, and may be relied upon by, the Company, including its
representatives, agents and counsel, and counsel for the Selling Stockholder, including in connection with the preparation of the Registration Statement and any related amendment or prospectus supplement; 

 

	 	•	 	consents to the disclosure of the information provided in this Questionnaire (other than date of birth, telephone, and e-mail information) and the inclusion of such information in
the Registration Statement and any amendment or prospectus supplement; and 

  

	 	•	 	agrees to promptly notify the Company of any inaccuracies or changes in the information provided in this Questionnaire that may occur subsequent to the date of this Questionnaire at any time during the time the
Registration Statement remains effective, and to provide any additional information as the Company or its representatives, agents or counsel may reasonably request. 

If the Company is required to file a new or additional registration statement to register Registrable Securities owned by the Selling
Stockholder, the undersigned hereby agrees to complete and return to the Company, upon the request of the Company, a new questionnaire (in a form substantially similar to this Questionnaire). 

If the Selling Stockholder transfers all or any portion of its Registrable Securities after the date of this Questionnaire, the undersigned
hereby agrees to notify the transferee(s) at the time of transfer of its obligations under this Questionnaire. 
  

							
	Dated:                                   
                                      	 	
                   
     Selling Stockholder:
	 	  

							
				
		 		 	 By:
	 	  

		 		 	 Name:
	 	  

		 		 	 Title:
	 	  

 Please fax or e-mail a copy of the completed and executed
Questionnaire by 
 November 18, 2016 and return the original to: 

Akin Gump Strauss Hauer & Feld LLP 

1111 Louisiana Street, 44th Floor 

Houston, Texas 77002-5200 
 Attn:
Cynthia Angell 
 Telephone: (713) 250-2245 

Fax: (713) 236-0822 

Email: cangell@akingump.com 

 EXHIBIT A 

Definition of “Beneficial Ownership” 

A “beneficial owner” of a security includes: 
  

	 	1.	Any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: 

  

	 	(a)	voting power which includes the power to vote, or to direct the voting of, such security; and/or, 

  

	 	(b)	investment power which includes the power to dispose, or to direct the disposition of, such security. 

Please note that either voting power or investment power, or both, is sufficient for you to be considered the beneficial owner of shares. 

 

	 	2.	Any person who, directly or indirectly, creates or uses a trust, proxy, power of attorney, pooling arrangement or any other contract, arrangement, or device with the purpose of effect of divesting such person of
beneficial ownership of a security or preventing the vesting of such beneficial ownership as part of a plan or scheme to evade the reporting requirements of section 13(d) or (g) of the Securities Exchange Act of 1934, as amended.

  

	 	3.	Any person who has the right to acquire “beneficial ownership” (defined by reference to paragraph (1)) of such security within 60 days, including but not limited to any right to acquire: (a) through the
exercise of any option, warrant or right; (b) through the conversion of a security; (c) pursuant to the power to revoke a trust, discretionary account, or similar arrangement; or (d) pursuant to the automatic termination of a trust,
discretionary account or similar arrangement; provided, however, any person who acquires a security or power specified in clauses (a), (b) or (c), with the purpose or effect of changing or influencing the control of the issuer, or in connection with
or as a participant in any transaction having such purpose or effect, immediately upon such acquisition shall be deemed to be the beneficial owner of the securities which may be acquired through the exercise or conversion of such security or power.EX-10.1

 Exhibit 10.1 

MEI PHARMA, INC. 

AMENDED AND RESTATED 

2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN 

Section 1. Purpose 
 The Plan authorizes
the Compensation Committee to provide Advisors, Employees and Non-Employee Directors that are providing, or have agreed to provide, services to the Company or its Affiliates, who are in a position to contribute to the long-term success of the
Company or its Affiliates, with Grants. The Company believes that this incentive program will cause those Advisors, Employees and Non-Employee Directors to increase their interest in the welfare of the Company and its Affiliates, and aid in
attracting, retaining and motivating Advisors, Employees and Non-Employee Directors of outstanding ability. 
 The Plan was originally
effective as of December 9, 2008 upon approval by the stockholders of the Company. The Plan was amended and restated effective October 21, 2011, but the share increase was effective December 1, 2011 upon approval by the stockholders of the Company.
The Plan was amended and restated effective January 29, 2013, but the share increase was effective March 26, 2013 upon approval by the stockholders of the Company. The Plan was further amended and restated effective December 3, 2014 and December 3,
2015, in each case upon approval by the stockholders of the Company. This amendment and restatement of the Plan is effective as of the Restatement Effective Date, subject to approval by the Company’s stockholders; provided, however, that
if this amendment and restatement is not so approved, the prior version of the Plan (as in effect immediately prior to the Board’s approval of this amendment and restatement) shall continue to operate according to its terms. 

Section 2. Definitions 
 Capitalized terms
used herein shall have the meanings set forth in this Section. 
 (a) “Advisor” shall mean advisors who render bona fide services
to the Company or its subsidiaries where the services are not in connection with the offer and sale of securities in a capital-raising transaction and the Advisors do not directly or indirectly promote or maintain a market for the Company’s
securities. 
 (b) “Affiliate” shall mean any Person which is included as a member with the Company in a controlled group of
corporations, within the meaning of Code section 414(b), or which is a trade or business (whether or not incorporated) included with the Company in a group of trades or business under common control, within the meaning of Code section 414(c);
provided, however, that in applying Code sections 1563(a)(1), (2) and (3) for purposes of determining a controlled group of corporations under Code section 414(b), the language “at least 20 percent” is used instead of
“at least 80 percent” each place it appears in Code sections 1563(a)(1), (2) and (3), and in applying Treas. Reg. section 1.414(c)-2 for purposes of determining trades or businesses (whether or not

  
 1 

 
incorporated) that are under common control for purposes of Code section 414(c), the language “at least 20 percent” is used instead of “at least 80 percent” each place it
appears in Treas. Reg. section 1.414(c)-2. 
 (c) “Board” shall mean the Board of Directors of the Company. 

(d) “Cash-Based Award” shall mean any Grant denominated in cash, as described in Section 9. 

(e) “Cause” shall have the meaning ascribed thereto in any effective employment or service agreement between the Company and the
Grantee, or if no employment agreement is in effect that contains a definition of cause, then Cause shall mean a finding by the Compensation Committee, in its sole and absolute discretion, that the Grantee has (i) committed a felony or a crime
involving moral turpitude, (ii) committed any act of gross negligence or fraud, (iii) failed, refused or neglected to substantially perform his duties (other than by reason of a physical or mental impairment) or to implement the directives of the
Company, (iv) materially violated any policy of the Company, or (v) engaged in conduct that is materially injurious to the Company, monetarily or otherwise. 

(f) “Change in Control” shall be deemed to have occurred if: 

(i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a “beneficial owner” (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change in Control shall not be
deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the
transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors. 

(ii) The consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders of the Company,
immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would
be entitled in the election of directors, or where the members of the Board, immediately prior to the merger or consolidation, would not, immediately after the merger or consolidation, constitute a majority of the board of directors of the surviving
corporation, (B) a sale or other disposition of all or substantially all of the assets of the Company, or (C) a liquidation or dissolution of the Company. 

  
 2 

 Notwithstanding the foregoing definition of Change in Control, the Compensation Committee may modify the
definition of Change in Control for a particular Grant as it deems appropriate to comply with Code section 409A or otherwise. 
 (g)
“Code” shall mean the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder. 
 (h)
“Company” shall mean MEI Pharma, Inc., a corporation organized under the laws of the State of Delaware. 
 (i) “Compensation
Committee” shall mean the members of the Board appointed by the Board to serve as the Compensation Committee with responsibility for the administration of the Plan, or if no such members of the Board are appointed, then the Compensation
Committee shall consist of all of the members of the Board. In any case, the Board shall approve and administer all grants made to Non-Employee Directors. The members of the Board appointed to serve as the Compensation Committee, if applicable,
should consist of two or more Persons who are “outside directors” as defined under Code section 162(m), and related Treasury regulations, and “non-employee directors” as defined under Rule 16b-3 under the Exchange Act. To the
extent that the Board or a subcommittee administers the Plan, references in the Plan to the “Compensation Committee” shall be deemed to refer to the Board or such subcommittee. 

(j) “Disability” or “Disabled” shall mean a Grantee’s becoming disabled within the meaning of Code section 22(e)(3)
or as otherwise determined by the Compensation Committee. 
 (k) “Employee” shall mean any individual that is providing, or has
agreed to provide, services to the Company or an Affiliate of the Company as an employee. 
 (l) “Exchange Act” shall mean the
Securities Exchange Act of 1934, as amended. 
 (m) “Exercise Price” shall mean the purchase price of a Share subject to an
Option, which shall not be less than the Fair Market Value of a Share as of the date an Option is granted. 
 (n) “Fair Market
Value” of a Share on any given date, unless the Compensation Committee determines otherwise with respect to a particular Grant, shall mean (i) if the principal trading market for the Shares is a national securities exchange, the last reported
sale price during regular trading hours thereof of a Share on the relevant date or (if there were no trades on that date) the last reported sales price during regular trading hours on the latest preceding date upon which a sale was reported, (ii) if
the Shares are not principally traded on such exchange, the mean between the last reported “bid” and “asked” prices of a Share during regular trading hours on the relevant date, as reported on the OTC Bulletin Board, or (iii) if
the Shares are not publicly traded or, if publicly traded, are not so reported, the Fair Market Value per share shall be as determined by the 

  
 3 

 
Compensation Committee pursuant to any reasonable valuation method authorized under the Code. 

(o) “Full Value Award” shall mean a Grant other than an Option or SAR, and which is settled in Shares. 

(p) “Grant” shall mean a grant of Options, SARs, Stock Awards, Stock Units, Cash-Based Awards or Other Stock-Based Awards under the
Plan. 
 (q) “Grant Letter” shall mean a letter, certificate or other agreement accepted by the Grantee (which may also be in
electronic form), evidencing the making of a Grant hereunder and containing such terms and conditions, not inconsistent with the express provisions of the Plan, as the Compensation Committee shall approve. 

(r) “Grantee” shall mean an Advisor, Employee or Non-Employee Director made a Grant under the Plan. 

(s) “ISO” shall mean any Option or portion thereof that meets the requirements of an incentive stock option under Code section 422
and that is designated by the Compensation Committee to be an ISO. 
 (t) “Non-Employee Director” shall mean a member of the Board
who is not an Employee. 
 (u) “Nonqualified Option” shall mean any Option or portion thereof that is not an ISO. 

(v) “Options” shall refer to options issued under and subject to the Plan. 

(w) “Other Stock-Based Award” shall mean any Grant based on, measured by or payable in Shares (other than those described in
Sections 5, 6, 7 and 8 of the Plan), as described in Section 9. 
 (x) “Person” shall mean an individual, partnership,
corporation, limited liability company or partnership, trust, unincorporated organization, joint venture, government (or agency or political subdivision thereof) or any other entity of any kind. 

(y) “Plan” shall mean this Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan as set forth herein and as
amended from time to time. 
 (z) “Restatement Effective Date” shall mean December 1, 2016, provided that this amendment and
restatement of the Plan is approved by the Company’s stockholders on such date. 
 (aa) “SAR” shall mean a stock appreciation
right with respect to a Share. 
 (bb) “Share” shall mean a share of common stock of the Company. 

(cc) “Stock Award” shall mean an award of Shares, with or without restrictions. 

  
 4 

 (dd) “Stock Unit” shall mean a unit that represents a hypothetical Share. 

(ee) “Substitute Awards” shall mean Grants made or Shares issued by the Company in assumption of, or in substitution or exchange
for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Company subsidiary or with which the Company or any subsidiary combines. 

Section 3. Shares Available under the Plan 
  

	 	(a)	Shares Authorized. Subject to adjustment as provided in Sections 3(b) and 13 below, as of the Restatement Effective Date, (i) 5,033,512 Shares, less (ii) one Share for every one Share that was subject to an
Option or SAR granted after August 31, 2016 and 1.25 Shares for every one Share that was subject to a Full Value Award granted after August 31, 2016, shall be authorized for Grants made under the Plan. A maximum of 2,000,000 Shares may be subject to
ISOs granted under the Plan. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares purchased in the open market or otherwise. 

 

	 	(b)	Share Counting. 

  

	 	(i)	For each Share that is subject to an Option or SAR granted after August 31, 2016, the Share limit referred above in Section 3(a) shall be reduced by one Share for every one Share that was subject to an Option or SAR and
for each Share that is subject to a Full Value Award granted after August 31, 2016, the Share limit shall be reduced by 1.25 Shares for every one Share that was subject to a Full Value Award. 

 

	 	(ii)	If any Shares subject to a Grant are forfeited, a Grant expires or a Grant is settled for cash (in whole or in part), then the Shares subject to such Grant shall, to the extent of such forfeiture, expiration or cash
settlement, be added to the Shares available for Grants under the Plan, subject to the mechanism set forth in Section 3(b)(iv). 

  

	 	(iii)	 Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares
that may be subject to Grants under the Plan: (A) Shares tendered by the Grantee or withheld by the Company in payment of the Exercise Price of an Option, (B) Shares tendered by the Grantee or withheld by the Company to satisfy any tax withholding
obligation with respect to Grants, (C) Shares subject to a SAR that are not issued in connection with its stock settlement on exercise thereof, and (D) Shares reacquired by the Company on the open market or otherwise using cash

  
 5 

	 	
proceeds from the exercise of Options. 

  

	 	(iv)	Any Shares that again become available for Grants under the Plan pursuant to this Section 3 shall be added as (A) one Share for every one Share subject to Options or SARs granted under the Plan, and (B) as 1.25 Shares
for every one Share subject to Full Value Awards granted under the Plan. 

  

	 	(c)	Substitute Awards. Substitute Awards shall not reduce the Shares authorized for grant under the Plan or the limitations on grants to a Grantee under Section 3(e), nor shall Shares subject to a Substitute Award be
added to the Shares available for issuance or transfer under the Plan as provided in Sections 3(a) and (b) above. Additionally, in the event that a company acquired by the Company or any Company subsidiary or with which the Company or any subsidiary
combines has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the
extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or
combination) may be used for Grants under the Plan and shall not reduce the Shares authorized for Grants under the Plan (and Shares subject to such Grants shall not be added to the Shares available for Grants under the Plan as provided in Sections
3(a) and (b) above); provided that Grants using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to
individuals who were not Employees or directors prior to such acquisition or combination. 

  

	 	(d)	Individual Limits on Grants to Non-Employee Directors. Notwithstanding any other provision of the Plan to the contrary, including but not limited to Section 3(e) below, the aggregate grant date fair value
(computed as of the date of grant in accordance with applicable financial accounting rules) of all Grants granted to any Non-Employee Director during any single calendar year, plus the sum of all cash payments paid or payable to such director for
such year (including but not limited to annual retainer and similar fees) shall not exceed $400,000. 

  

	 	(e)	 Individual Limits on Grants to Advisors and Employees. Subject to adjustment as provided in Section 13, no
Advisor or Employee may be granted (i) Options or SARs during any calendar year with respect to more than 2,000,000 Shares and (ii) Full Value Awards during any calendar year that are intended to comply with the performance-based exception under
Code section 162(m) and are denominated 

  
 6 

	 	
in Shares under which more than 2,000,000 Shares may be earned for each 12 months in the vesting period or performance period. During any calendar year, no Advisor or Employee may be granted
awards that are intended to comply with the performance-based exception under Code section 162(m) and are denominated in cash under which more than $3,000,000 may be earned for each 12 months in the performance period. Each of the limitations in
this Section 3(e) shall be multiplied by two with respect to Grants made to an Employee during the first calendar year in which the Employee commences employment or service with the Company and its subsidiaries. If a Grant is cancelled, the
cancelled Grant shall continue to be counted toward the applicable limitation in this Section 3(e). 

 Section 4. Administration of the
Plan 
 (a) Authority of the Compensation Committee. The Plan shall be administered by the Compensation Committee. The
Compensation Committee shall have full and final authority to take the following actions, in each case subject to and consistent with the provisions of the Plan: 

(i) to select the Advisors, Employees and Non-Employee Directors to whom Grants may be made; 

(ii) to determine the number of Shares subject to each such Grant; 

(iii) to determine the terms and conditions of any Grant made under the Plan; 

(iv) to determine whether to accelerate the exercisability of any or all applicable outstanding Grants at any time for any
reason; 
 (v) to determine the restrictions or conditions related to the delivery, holding and disposition of Shares
acquired pursuant to a Grant; 
 (vi) to prescribe the form of each Grant Letter; 

(vii) to adopt, amend, suspend, waive and rescind such rules and regulations and appoint such agents as the Compensation
Committee may deem necessary or advisable to administer the Plan; 
 (viii) to correct any defect or supply any omission or
reconcile any inconsistency in the Plan and to construe and interpret the Plan and any Grant, Grant Letter or other instrument hereunder; and 

(ix) to make all other decisions and determinations as may be required under the terms of the Plan or as the Compensation
Committee may deem necessary or advisable for the administration of the Plan. 
 All Grants shall be made conditional upon the
Grantee’s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations of the Compensation Committee shall be final and binding on the Grantee, his or her beneficiaries and any other Person having or claiming
an interest under such Grant. 

  
 7 

 (b) Manner of Exercise of Compensation Committee Authority. Any action of the Compensation
Committee with respect to the Plan shall be final, conclusive and binding on all Persons, including the Company, its Affiliates, Grantees, or any Person claiming any rights under the Plan from or through any Grantee, except to the extent the
Compensation Committee may subsequently modify, or take further action not inconsistent with, its prior action. If not specified in the Plan, the time at which the Compensation Committee must or may make any determination shall be determined by the
Compensation Committee, and any such determination may thereafter be modified by the Compensation Committee. The express grant of any specific power to the Compensation Committee, and the taking of any action by the Compensation Committee, shall not
be construed as limiting any power or authority of the Compensation Committee. The Compensation Committee may delegate to officers or managers of the Company or any Affiliate of the Company the authority, subject to such terms as the Compensation
Committee shall determine, to perform such functions as the Compensation Committee may determine, to the extent permitted under applicable law. 

(c) Limitation of Liability. Each member of the Compensation Committee shall be entitled to, in good faith, rely or act upon any report
or other information furnished to him by any officer or other employee of the Company or any of its Affiliates, the Company’s independent certified public accountants or any executive compensation consultant, legal counsel or other professional
retained by the Company to assist in the administration of the Plan. To the fullest extent permitted by applicable law, no member of the Compensation Committee, nor any officer or employee of the Company acting on behalf of the Compensation
Committee, shall be personally liable for any action, determination or interpretation taken or made in good faith with respect to the Plan, and all members of the Compensation Committee and any officer or employee of the Company acting on its behalf
shall, to the extent permitted by law, be fully indemnified and protected by the Company with respect to any such action, determination or interpretation. 

Section 5. Options 
 The Compensation
Committee may grant Options to an Employee, Advisor or member of the Board upon such terms as the Compensation Committee deems appropriate. The following provisions are applicable to Options: 

(a) Number of Shares. The Compensation Committee shall determine the number of Shares that will be subject to each Grant of Options to
an Employee, Advisor or member of the Board. 
 (b) Type of Option and Price. 

(i) The Compensation Committee may grant ISOs or Nonqualified Stock Options or any combination of the two, all in accordance with the terms
and conditions set forth herein. ISOs may be granted only to employees of the Company or its parent or 

  
 8 

 
subsidiary corporations, as defined in Code section 424. Nonqualified Options may be granted to Employees, Advisors or members of the Board. 

(ii) The Exercise Price of Shares subject to an Option shall be determined by the Compensation Committee and may be equal to or greater than
the Fair Market Value of a Share on the date the Option is granted. However, an ISO may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the
Company, or any parent or subsidiary corporation of the Company, as defined in Code section 424, unless the Exercise Price per Share is not less than 110% of the Fair Market Value of a Share on the date of grant. 

(iii) Each ISO shall provide that, if the aggregate Fair Market Value of the Shares on the date of the grant with respect to which ISOs are
exercisable for the first time by a Grantee during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary of the Company, exceeds $100,000, then the Option, as to the excess, shall be treated as a
Nonqualified Option. 
 (c) Option Term. The Compensation Committee shall determine the term of each Option. Notwithstanding the
foregoing, the term of any Option shall not exceed ten years from the date of grant. 
 (d) Option Termination. Except as provided
below, an Option may only be exercised while the Grantee is employed or engaged by the Company or any Affiliate as an Advisor, Employee or member of the Board. Unless otherwise determined by the Compensation Committee and set forth in a Grant
Letter, Options shall terminate on the earliest of: 
 (i) the date on which the Grantee is no longer employed or engaged by the Company and
any Affiliate on account of the Grantee’s termination for Cause. In addition, notwithstanding any other provisions of this Section 5, if the Compensation Committee determines that the Grantee has engaged in conduct that constitutes Cause at any
time while the Grantee is employed or engaged by the Company and any Affiliate or after the Grantee’s termination of employment or engagement, any Option held by the Grantee shall immediately terminate and the Grantee shall automatically
forfeit all Shares underlying any exercised portion of an Option for which the Company has not yet delivered the Share certificates, upon refund by the Company of the Exercise Price paid by the Grantee for such Shares. Upon any exercise of an
Option, the Company may withhold delivery of Share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture; 

(ii) the 91st day following the date the Grantee is no longer employed or engaged by the Company and any Affiliate for any reason other than
Cause, death, or Disability; provided, however, that in all cases the portion of any Option that is not vested on the date of termination of employment or engagement shall terminate immediately upon such termination; 

  
 9 

 (iii) the first anniversary of the date the Grantee’s employment or engagement by the
Company and any Affiliate terminates on account of the Grantee’s death or Disability; provided, however, that the portion of any Option that is not vested on the date of such termination of employment or engagement shall terminate
immediately upon such termination; 
 (iv) the tenth anniversary of the date of grant as set forth in the Grant Letter; and 

(v) cancellation, termination or expiration of the Options pursuant to action taken by the Compensation Committee in accordance with Section
13. 
 Notwithstanding the foregoing, in the event that on the last business day of the term of an Option (other than an ISO) (i) the
exercise of the Option is prohibited by applicable law or (ii) Shares may not be purchased or sold by certain employees or directors of the Company due to the “black-out period” of a Company policy or a “lock-up” agreement
undertaken in connection with an issuance of securities by the Company, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition, black-out period or lock-up agreement. 

For purposes of the Plan, employment or engagement by the Company and any Affiliate shall mean employment or service as an Employee, Advisor
or member of the Board (so that, for purposes of exercising Options, a Grantee shall not be considered to have terminated his employment or engagement until the Grantee ceases to be an Employee, Advisor and member of the Board), unless the
Compensation Committee determines otherwise. 
 (e) Exercise of Options. Only the vested portion of any Option may be exercised. A
Grantee may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Grantee shall pay the Exercise Price for an Option as specified by the Compensation Committee (i) in cash, (ii)
unless the Compensation Committee determines otherwise, by delivering Shares owned by the Grantee and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Compensation
Committee) to ownership of Shares having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or
(iv) by such other method as the Compensation Committee may approve. In addition, in the event the Compensation Committee so determines, to the extent an Option is at the time exercisable for vested shares of Company Stock, all or any part of that
vested portion may be surrendered to the Company for an appreciation distribution payable in Shares with a Fair Market Value at the time of the Option surrender equal to the dollar amount by which the then Fair Market Value of the Shares subject to
the surrendered portion exceeds the aggregate Exercise Price payable for those Shares. Shares used to exercise an Option shall have been held by the Grantee for the requisite period of time necessary to avoid adverse accounting

  
 10 

 
consequences to the Company with respect to the Option. Payment for the Shares to be issued or transferred pursuant to the Option, and any required withholding taxes, must be received by the
Company by the time specified by the Compensation Committee depending on the type of payment being made, but in all cases prior to the issuance or transfer of such Shares. 

Notwithstanding the foregoing, a Grant Letter may provide that if on the last day of the term of an Option the Fair Market Value of one Share
exceeds the Exercise Price per Share, the Grantee has not exercised the Option (or a tandem SAR, if applicable) and the Option has not expired, the Option shall be deemed to have been exercised by the Grantee on such day with payment made by
withholding Shares otherwise issuable in connection with the exercise of the Option. In such event, the Company shall deliver to the Grantee the number of Shares for which the Option was deemed exercised, less the number of Shares required to be
withheld for the payment of the total Exercise Price and required withholding taxes; provided, however, any fractional Share shall be settled in cash. 

Section 6. Stock Awards 
 The Compensation
Committee may issue or transfer Shares to an Employee, Advisor or member of the Board under a Stock Award, upon such terms as the Compensation Committee deems appropriate. The following provisions are applicable to Stock Awards: 

(a) General Requirements. Shares issued or transferred pursuant to Stock Awards may be issued or transferred for consideration or for
no consideration, and subject to restrictions or no restrictions, as determined by the Compensation Committee. The Compensation Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse
over a period of time or according to such other criteria as the Compensation Committee deems appropriate, including, without limitation, restrictions based upon the achievement of specific performance goals. The period of time during which the
Stock Awards will remain subject to restrictions will be designated in the Grant Letter as the “Restriction Period.” 
 (b)
Number of Shares. The Compensation Committee shall determine the number of Shares to be issued or transferred pursuant to a Stock Award and the restrictions applicable to such Shares. 

(c) Requirement of Employment or Service. If the Grantee is no longer employed or engaged by the Company or any Affiliate during a
period designated in the Grant Letter as the Restriction Period, or if other specified conditions are not met, the Stock Award shall terminate as to all Shares covered by the Grant as to which the restrictions have not lapsed, and those Shares must
be immediately returned to the Company. The Compensation Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate. 

  
 11 

 (d) Restrictions on Transfer and Legend on Stock Certificate. During the Restriction
Period, a Grantee may not sell, assign, transfer, pledge or otherwise dispose of the Shares of a Stock Award except under Section 14(b) below. Unless otherwise determined by the Compensation Committee, the Company will retain possession of
certificates for Shares of Stock Awards until all restrictions on such Shares have lapsed. Each certificate for a Stock Award, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the Grant. The Grantee
shall be entitled to have the legend removed from the stock certificate covering the Shares subject to restrictions when all restrictions on such Shares have lapsed. The Compensation Committee may determine that the Company will not issue
certificates for Stock Awards until all restrictions on such Shares have lapsed. 
 (e) Right to Vote and to Receive Dividends.
Unless the Compensation Committee determines otherwise, during the Restriction Period, the Grantee shall have the right to vote Shares of Stock Awards and to receive any dividends or other distributions paid on such Shares, subject to any
restrictions deemed appropriate by the Compensation Committee, including, without limitation, the achievement of specific performance goals. Notwithstanding the provisions of this Section, any cash dividends, stock and any other property (other than
cash) distributed as a dividend or otherwise with respect to any Stock Award that vests based on achievement of performance goals shall either (i) not be paid or credited or (ii) be accumulated and subject to restrictions and risk of forfeiture to
the same extent as the Shares underlying the Stock Award with respect to which such cash, stock or other property has been distributed and shall be paid at the time such restrictions and risk of forfeiture lapse. 

(f) Lapse of Restrictions. All restrictions imposed on Stock Awards shall lapse upon the expiration of the applicable Restriction
Period and the satisfaction of all conditions, if any, imposed by the Compensation Committee. The Compensation Committee may determine, as to any or all Stock Awards, that the restrictions shall lapse without regard to any Restriction Period. 

Section 7. Stock Units 
 The Compensation
Committee may grant Stock Units, each of which shall represent one hypothetical Share, to an Employee, Advisor or member of the Board, upon such terms and conditions as the Compensation Committee deems appropriate. The following provisions are
applicable to Stock Units: 
 (a) Crediting of Units. Each Stock Unit shall represent the right of the Grantee to receive a Share or
an amount of cash based on the value of a Share, if and when specified conditions are met. All Stock Units shall be credited to bookkeeping accounts established on the Company’s records for purposes of the Plan. 

(b) Terms of Stock Units. The Compensation Committee may grant Stock Units that are payable if specified performance goals or other
conditions are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period or 

  
 12 

 
other period, or payment may be deferred to a date authorized by the Compensation Committee. The Compensation Committee shall determine the number of Stock Units to be granted and the
requirements applicable to such Stock Units. 
 (c) Requirement of Employment or Service. If the Grantee is no longer employed or
engaged by the Company or any Affiliate prior to the vesting of Stock Units, or if other conditions established by the Compensation Committee are not met, the Grantee’s Stock Units shall be forfeited. The Compensation Committee may, however,
provide for complete or partial exceptions to this requirement as it deems appropriate. 
 (d) Payment With Respect to Stock Units.
Payments with respect to Stock Units shall be made in cash, Shares or any combination of the foregoing, as the Compensation Committee shall determine. 

Section 8. Stock Appreciation Rights 
 The
following provisions are applicable to SARs: 
 (a) General Requirements. The Compensation Committee may grant SARs to an Employee,
Advisor or member of the Board separately or in tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted or at any time thereafter while the Option remains
outstanding; provided, however, that, in the case of an ISO, SARs may be granted only at the time of the grant of the ISO. The Compensation Committee shall establish the base amount of the SAR at the time the SAR is granted, which
shall be equal to or greater than the Fair Market Value of a Share as of the date of grant of the SAR. The base amount of each SAR shall be equal to the per Share Exercise Price of the related Option, provided such Exercise Price is equal to or
greater than the Fair Market Value of a Share as of the date of grant of the SAR or, if there is no related Option, an amount equal to or greater than the Fair Market Value of a Share as of the date of grant of the SAR. No SAR shall have a term that
is greater than ten years. 
 Notwithstanding the foregoing, in the event that on the last business day of the term of a SAR (x) the
exercise of the SAR is prohibited by applicable law or (y) Shares may not be purchased or sold by certain employees or directors of the Company due to the “black-out period” of a Company policy or a “lock-up” agreement undertaken
in connection with an issuance of securities by the Company, the term shall be extended for a period of 30 days following the end of the legal prohibition, black-out period or lock-up agreement. 

(b) Tandem SARs. In the case of tandem SARs, the number of SARs granted to a Grantee that shall be exercisable during a specified
period shall not exceed the number of Shares that the Grantee may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the Shares covered by such Option shall terminate. Upon the
exercise of SARs, the related Option shall terminate to the extent of an equal number of Shares. 

  
 13 

 (c) Exercisability. A SAR shall be exercisable during the period specified by the
Compensation Committee in the Grant Letter and shall be subject to such vesting and other restrictions as may be specified in the Grant Letter. The Compensation Committee may accelerate the exercisability of any or all outstanding SARs at any time
for any reason. SARs may only be exercised while the Grantee is employed or engaged by the Company or Affiliate or during the applicable period after termination of employment or engagement as described in Section 5(c) above. A tandem SAR shall be
exercisable only during the period when the Option to which it is related is also exercisable. 
 A Grant Letter may provide that if on the
last day of the term of a SAR the Fair Market Value of one Share exceeds the base amount per Share of the SAR, the Grantee has not exercised the SAR or the tandem Option (if applicable), and the SAR has not otherwise expired, the SAR shall be deemed
to have been exercised by the Grantee on such day. In such event, the Company shall make payment to the Grantee in accordance with this Section, reduced by the number of Shares (or cash) required for withholding taxes; any fractional Share shall be
settled in cash. 
 (d) Grants to Non-Exempt Employees. Notwithstanding the foregoing, SARs granted to persons who are non-exempt
employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such SARs may become exercisable, as determined by the Compensation Committee, upon the
Grantee’s death, Disability or retirement, or upon a Change in Control or other circumstances permitted by applicable regulations). 

(e) Value of SARs. When a Grantee exercises SARs, the Grantee shall receive in settlement of such SARs an amount equal to the value of
the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair Market Value of the underlying Share on the date of exercise of the SAR exceeds the base amount of the SAR as described in
subsection (a) above. 
 (f) Form of Payment. The appreciation in a SAR shall be paid in Shares, cash or any combination of the
foregoing, as the Compensation Committee shall determine. For purposes of calculating the number of Shares to be received, Shares shall be valued at their Fair Market Value on the date of exercise of the SAR. 

Section 9. Cash-Based Awards and Other Stock-Based Awards 

The Compensation Committee may grant Cash-Based Awards or Other Stock-Based Awards to any Employee, Advisor or member of the Board, on such
terms and conditions as the Compensation Committee shall determine. Cash-Based Awards and Other Stock-Based Awards may be awarded subject to the achievement of performance goals or other conditions and may be payable in cash, Company Stock or any
combination of the foregoing, as the Compensation Committee shall determine. 
 Section 10. Dividend Equivalents 

  
 14 

 The Compensation Committee may grant Dividend Equivalents in connection Stock Units or Other
Stock-Based Awards. No Dividend Equivalents or dividends may be granted in connection with Options or SARs. Dividend Equivalents may be paid currently or accrued as contingent cash obligations and may be payable in cash or Shares, and upon such
terms as the Compensation Committee may establish, including, without limitation, the achievement of specific performance goals. Notwithstanding the foregoing in this Section 10, any Dividend Equivalents granted in connection with Stock Units or
Other Stock-Based Awards that are subject to specified performance goals shall be payable only if and to the extent the underlying Stock Units or Other Stock-Based Awards are payable, as determined by the Compensation Committee. 

Section 11. Qualified Performance-Based Compensation 

The Compensation Committee may determine that Stock Awards, Stock Units, Cash-Based Awards, Other Stock-Based Awards and Dividend Equivalents
granted to an Employee shall be considered “qualified performance-based compensation” under Code section 162(m). The following provisions shall apply to Grants of Stock Awards, Stock Units, Cash-Based Awards, Other Stock-Based Awards and
Dividend Equivalents that are to be considered “qualified performance-based compensation” under Code section 162(m): 
 (a)
Performance Goals. 
 (i) When Stock Awards, Stock Units, Cash-Based Awards, Other Stock-Based Awards or Dividend Equivalents that
are to be considered “qualified performance-based compensation” are granted, the Compensation Committee shall establish in writing (A) the objective performance goals that must be met, (B) the performance period during which the
performance will be measured, (C) the threshold, target and maximum amounts that may be paid if the performance goals are met, and (D) any other conditions that the Compensation Committee deems appropriate and consistent with the Plan and Code
section 162(m). 
 (ii) The business criteria may relate to the performance of the Company, or the performance of a parent company, a
subsidiary, division, business segment or business unit of the Company or a subsidiary, or based upon performance relative to performance of other companies or upon comparisons or any of the indicators of performance relative to performance of other
companies, or any combination of the foregoing. Any performance goals that are financial metrics, may be determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), in accordance with accounting principles
established by the International Accounting Standards Board (“IASB Principles”), or may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP or under IASB Principles. The
Compensation Committee shall use objectively determinable performance goals based on one or more of the following criteria: stock price, earnings per share, net earnings, operating earnings, earnings before income taxes, EBITDA (earnings before
income tax 

  
 15 

 
expense, interest expense, and depreciation and amortization expense), return on assets, shareholder return, return on equity, growth in assets, unit volume, sales or market share, or strategic
business criteria consisting of one or more objectives based on meeting specified revenue goals, market penetration goals, geographic business expansion goals, cost targets or goals relating to acquisitions or divestitures; pre- or after-tax income
or loss (before or after allocation of corporate overhead and bonus); appreciation in and/or maintenance of the price of the Shares or any other publicly-traded securities of the Company; improvement in or attainment of expense levels or working
capital levels, including cash, inventory and accounts receivable; general and administrative expense savings; year-end cash; regulatory achievements (including submitting or filing applications or other documents with regulatory authorities or
receiving approval of any such applications or other documents and passing pre-approval inspections (whether of the Company or the Company’s third-party manufacturer) and validation of manufacturing processes (whether the Company’s or the
Company’s third-party manufacturer’s); clinical achievements (including initiating clinical studies, initiating enrollment, completing enrollment or enrolling particular numbers of subjects in clinical studies, completing phases of a
clinical study (including the treatment phase), or announcing or presenting preliminary or final data from clinical studies, in each case, whether on particular timelines or generally); strategic partnerships or transactions (including in-licensing
and out-licensing of intellectual property); establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company’s products (including with group purchasing organizations, distributors and
other vendors); co-development, co-marketing, profit sharing, joint venture or other similar arrangements; financing and other capital raising transactions (including sales of the Company’s equity or debt securities); debt level year-end cash
position; competitive market metrics; timely completion of new product roll-outs; sales or licenses of the Company’s assets (including its intellectual property, whether in a particular jurisdiction or territory or globally, or through
partnering transactions); royalty income; implementation, completion or attainment of measurable objectives with respect to research, development, manufacturing, commercialization, products or projects, acquisitions and divestitures. The
Compensation Committee may provide for exclusion of the impact of an event or occurrence which the Compensation Committee determines should appropriately be excluded, including (A) restructurings, discontinued operations, extraordinary items, and
other unusual, infrequently occurring or non-recurring charges, (B) an event either not directly related to the operations of the Company, Company subsidiary, division, business segment or business unit or not within the reasonable control of
management, or (C) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles. 

(b) Establishment of Goals. The Compensation Committee shall establish the performance goals (and any exclusions) in writing either
before the beginning of the performance period or during a period ending no later than the earlier of (i) 90 days after 

  
 16 

 
the beginning of the performance period or (ii) the date on which 25% of the performance period has been completed, or such other date as may be required or permitted under applicable regulations
under Code section 162(m). The performance goals shall satisfy the requirements for “qualified performance-based compensation,” including the requirement that the achievement of the goals be substantially uncertain at the time they are
established and that the goals be established in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Compensation Committee shall not have discretion
to increase the amount of compensation that is payable upon achievement of the designated performance goals. 
 (c) Announcement of
Grants. The Compensation Committee shall certify and announce the results for each performance period to all Grantees after the announcement of the Company’s financial results for the performance period. If and to the extent that the
Compensation Committee does not certify that the performance goals have been met, the grants of Stock Awards, Stock Units, Cash-Based Awards, Other Stock-Based Awards and Dividend Equivalents for the performance period shall be forfeited or shall
not be made, as applicable. If Dividend Equivalents are granted as “qualified performance-based compensation” under Code section 162(m), a Grantee may not accrue more than $1,000,000 of such Dividend Equivalents during any calendar year.

 (d) Death, Disability or Other Circumstances. The Compensation Committee may provide that Stock Awards, Stock Units, Cash-Based
Awards, Other Stock-Based Awards and Dividend Equivalents shall be payable or restrictions on such Grants shall lapse, in whole or in part, in the event of the Grantee’s death or Disability during the performance period, or under other
circumstances consistent with the Treasury regulations and rulings under Code section 162(m). 
 Section 12. Deferrals 

The Compensation Committee may permit or require a Grantee to defer receipt of the payment of cash or the delivery of Shares that would
otherwise be due to such Grantee in connection with any Stock Units, Cash-Based Awards, or Other Stock-Based Awards. If any such deferral election is permitted or required, the Compensation Committee shall establish rules and procedures for such
deferrals and may provide for interest or other earnings to be paid on such deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of Code section 409A. 

Section 13. Adjustment Upon Changes in Capitalization. 

In the event any recapitalization, forward or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, exchange
or issuance of Shares or other securities, any stock dividend or other special and nonrecurring dividend or distribution (whether in the form of cash, securities or other property other than a regular cash dividend), liquidation, dissolution, or
other similar transactions or events, affects the 

  
 17 

 
Shares or the value thereof, then the Compensation Committee shall make such adjustment, in such manner as the Compensation Committee deems appropriate, in order to prevent dilution or
enlargement of the rights of Grantees under the Plan, including adjustment in (i) the number and kind of Shares deemed to be available thereafter for Grants under Section 3, (ii) the number and kind of Shares that may be delivered or deliverable in
respect of outstanding Grants, and (iii) the price per share or the applicable market value of such Grants. In addition, the Compensation Committee shall make such adjustments as are appropriate in the terms and conditions of, and the criteria
included in, Grants (including, without limitation, cancellation of Grants in exchange for the in-the-money value, if any, of the vested portion thereof, cancellation of unvested Grants for no consideration, cancellation of out-of-the-money Grants
for no consideration, substitution of Grants using securities of a successor or other entity, acceleration of the time that Grants expire, or adjustment of performance targets) in recognition of unusual or nonrecurring events (including, without
limitation, a Change in Control or an event described in the preceding sentence) affecting the Company or any Affiliate of the Company or the financial statements of the Company or any Affiliate of the Company, or in response to changes in
applicable laws, regulations or accounting principles. Any adjustments to outstanding Grants shall be consistent with Code section 409A or 424, to the extent applicable. Any adjustments determined by the Compensation Committee shall be final,
binding and conclusive. 
 Section 14. Restrictions on Shares. 

(a) Restrictions on Issuing Shares. No Shares shall be issued or transferred under the Plan unless and until all applicable legal
requirements have been complied with to the satisfaction of the Compensation Committee. The Compensation Committee shall have the right to condition any Grant on the Grantee’s undertaking in writing to comply with such restrictions on any
subsequent disposition of the Shares issued or transferred thereunder as the Compensation Committee shall deem necessary or advisable as a result of any applicable law, regulation or official interpretation thereof. 

(b) Transfer Restrictions. 

(i) Nontransferability of Grants. Except as provided below, only the Grantee may exercise rights under a Grant during the
Grantee’s lifetime. No Grant under the Plan and no Shares that have not been issued or as to which any applicable restriction, performance or deferral period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered,
except (A) by will or by the laws of descent and distribution or (B) with respect to Grants other than ISOs, pursuant to a domestic relations order. When a Grantee dies, the personal representative or other Person entitled to succeed to the rights
of the Grantee may exercise such rights. Any such successor must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Grantee’s will or under the applicable laws of descent and distribution. 

  
 18 

 (ii) Transfer of Nonqualified Stock Options. Notwithstanding (i) above, the Compensation
Committee may provide, in a Grant Letter, that a Grantee may transfer Nonqualified Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws,
according to such terms as the Compensation Committee may determine; provided that the Grantee receives no consideration for the transfer of the Nonqualified Option and the transferred Nonqualified Option shall continue to be subject to the same
terms and conditions as were applicable to the Nonqualified Option immediately before the transfer. 
 (c) ISO Notice. A Grantee
shall notify the Company of any disposition of Shares acquired upon exercise of an ISO if such disposition occurs within one year of the date of such exercise or within two years of the date of grant of such ISO. The Company may impose such
procedures as it determines may be necessary to ensure that such notification is made. 
 (d) Requirements for Issuance or Transfer of
Shares. No Shares shall be issued or transferred in connection with any Grant made hereunder unless and until all legal requirements applicable to the issuance or transfer of such Shares have been complied with to the satisfaction of the
Compensation Committee. The Compensation Committee shall have the right to condition any Grant on the Grantee’s undertaking in writing to comply with such restrictions on his or her subsequent disposition of the Shares as the Compensation
Committee shall deem necessary or advisable, and certificates representing such Shares may be legended to reflect any such restrictions. Certificates representing Shares issued or transferred under the Plan may be subject to such stop-transfer
orders and other restrictions as the Compensation Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon. 

Section 15. Withholding of Taxes. 
 All
Grants made under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding requirements. The Company may require that the Grantee or other Person receiving or exercising Grants pay to the Company or any
Affiliate the amount of any federal, state or local taxes that the Company or any Affiliate is required to withhold with respect to such Grants, or the Company or any Affiliate may deduct from other wages paid by the Company or any Affiliate the
amount of any withholding taxes due with respect to such Grants. If the Compensation Committee so permits, a Grantee may elect to satisfy the applicable tax withholding obligation with respect to a Grant by having Shares withheld up to an amount
that does not exceed the Grantee’s minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities or such other rate that will not cause an adverse accounting consequence or cost. The election must be in a
form and manner prescribed by the Compensation Committee and may be subject to the prior approval of the Compensation Committee. 

  
 19 

 Section 16. Consequences of a Change in Control. 

The Compensation Committee may provide in a Grant Letter or otherwise terms under which Grants may vest and, as applicable, be exercisable or
payable in the event of a Change in Control or in the event of a Grantee’s termination of employment or engagement by the Company and any Affiliate in connection with, upon or within a specified time period after a Change of Control. In
addition, in the event of a Change in Control, the Compensation Committee may take one or more of the following actions with respect to any or all outstanding Grants: the Compensation Committee may (i) require that Grantees surrender their
outstanding vested Options and SARs in exchange for one or more payments by the Company, in cash or Shares as determined by the Compensation Committee, in an amount equal to the amount by which the then Fair Market Value of the Shares subject to the
Grantee’s unexercised, vested Options and SARs exceeds the Exercise Price of the vested Options or the base amount of the vested SARs, as applicable, (ii) provide for the cancellation of unvested Grants for no consideration, (iii) provide for
the cancellation of out-of-the-money Grants for no consideration, (iv) after giving Grantees an opportunity to exercise their outstanding Options and SARs, terminate any or all unexercised Options and SARs at such time as the Compensation Committee
deems appropriate, or (v) determine that outstanding Options and SARs that are not exercised shall be assumed by, or replaced with comparable options or rights by, the surviving corporation, (or a parent or subsidiary of the surviving corporation),
and other outstanding Grants that remain in effect after the Change in Control shall be converted to similar grants of the surviving corporation (or a parent or subsidiary of the surviving corporation). Such surrender or termination shall take place
as of the date of the Change in Control or such other date as the Compensation Committee may specify (subject to consummation of the Change in Control). 

Section 17. General Provisions 
 (a)
Grant Letter. Each Grant shall be evidenced by a Grant Letter. The terms and provisions of such Grant Letters may vary among Grantees and among different Grants made to the same Grantee. 

(b) No Right to Employment. The making of a Grant in any year shall not give the Grantee any right to similar grants in future years,
any right to continue such Grantee’s employment relationship with the Company or its Affiliates, or, until Shares are issued, any rights as a stockholder of the Company. All Grantees shall remain subject to discharge to the same extent as if
the Plan were not in effect. For purposes of the Plan, a sale of any Affiliate of the Company that employs or engages a Grantee shall be treated as the termination of such Grantee’s employment or engagement, unless the Grantee shall otherwise
continue to provide services to the Company or another subsidiary of the Company as an employee or director. 
 (c) No Fractional
Shares. No fractional Shares shall be issued or delivered pursuant to the Plan or any Grant. Except as otherwise provided under the Plan, the Compensation 

  
 20 

 
Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional Shares or whether such fractional Shares or any rights thereto shall be
forfeited or otherwise eliminated. 
 (d) No Funding. No Grantee, and no beneficiary or other Persons claiming under or through the
Grantee, shall have any right, title or interest by reason of any Option to any particular assets of the Company or Affiliates of the Company, or any Shares allocated or reserved for the purposes of the Plan or subject to any Grant except as set
forth herein. The Company shall not be required to establish any fund or make any other segregation of assets to assure satisfaction of the Company’s obligations under the Plan. 

(e) Governing Law; Jurisdiction. The Plan shall be governed by and construed in accordance with the laws of the State of Delaware,
without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. To the
extent the Grantee is a party to an employment agreement with the Company or any of its subsidiaries that provides for binding arbitration of employment disputes, then any disputes between the Company and such Grantee arising under the Plan shall be
arbitrated in accordance with the procedures set forth in such employment agreement. 
 (f) Compliance with Law. The Plan, the
exercise of Options and SARs and the obligations of the Company to issue or transfer Shares under Grants shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With
respect to Persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In
addition, it is the intent of the Company that ISOs comply with the applicable provisions of Code section 422, that the Plan comply with the applicable provisions of Code section 162(m) and that, to the extent applicable, Grants be exempt from or
comply with the requirements of Code section 409A. Notwithstanding the foregoing, the Compensation Committee makes no representation that the Grants awarded under the Plan shall be exempt from or comply with Code section 409A and makes no
undertaking to preclude Code section 409A from applying to Grants awarded under the Plan. To the extent that any legal requirement of section 16 of the Exchange Act or Code sections 422, 162(m) or 409A as set forth in the Plan ceases to be required
under section 16 of the Exchange Act or Code sections 422, 162(m) or 409A, that Plan provision shall cease to apply. To the extent applicable, if on the date of a Grantee’s “separation from service” (as such term is defined under Code
section 409A), Shares (or shares of any other company required to be aggregated with the Company for purposes of Code section 409A and its corresponding regulations) are publicly-traded on an established securities market or otherwise and the
Grantee is a “specified employee” (as such term is defined in Code section 409A(a)(2)(B)(i) and its corresponding regulations) as determined by the Compensation Committee (or its delegate) in its discretion in accordance with the

  
 21 

 
requirements of Code sections 409A and 416, then all Grants that are deemed to be deferred compensation subject to the requirements of Code section 409A and payable within six months following
such Grantee’s “separation from service” shall be postponed for a period of six months following the Grantee’s “separation from service” with the Company, to the extent necessary to avoid the imposition of penalty taxes
thereunder. The Compensation Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Compensation Committee may, in its sole discretion, agree to
limit its authority under this Section 
 (g) Grants made in Connection with Corporate Transactions and Otherwise. Nothing contained
in the Plan shall be construed to (i) limit the right of the Compensation Committee to make Grants under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any
corporation, firm or association, including Grants to employees thereof who become Employees, or (ii) limit the right of the Company to grant stock options or make other awards outside of the Plan. The Compensation Committee may make a Grant to an
employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company, in substitution for awards made by such corporation.
Notwithstanding anything in the Plan to the contrary, the Compensation Committee may establish such terms and conditions of the new Grants as it deems appropriate, including setting the Exercise Price of Options at a price necessary to retain for
the Grantee the same economic value as the prior options. 
 (h) Application of Company Clawback Policy. All Grants under the Plan
are subject to the applicable provisions of the Company’s clawback or recoupment policy approved by the Board or the Compensation Committee; as such policy may be in effect from time to time, and will be subject to recoupment as may be required
by applicable law, regulation or listing exchange. 
 Section 18. Amendment or Termination. 

(a) Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without
stockholder approval if such approval is required in order to comply with the Code or other applicable law (including Rule 16b-3 under the Exchange Act), or to comply with applicable stock exchange requirements; and further provided that the Board
may not, without the approval of the Company’s stockholders, to the extent required by such applicable law, amend the Plan to (a) increase the number of Shares that may be the subject of Grants under the Plan (except for adjustments
pursuant to Section 13), (b) expand the types of awards available under the Plan, (c) materially expand the class of persons eligible to participate in the Plan, (d) amend Section 5 and Section 8 to eliminate the requirements relating to minimum
exercise price, minimum grant price and stockholder approval, (e) increase the 

  
 22 

 
maximum permissible term of any Option or the maximum permissible term of a SAR, (f) add performance goals to Section 11, (g) increase any of the limitations in Section 3, or (h) amend Section
18(b). 
 (b) No Repricing Without Stockholder Approval. Notwithstanding anything in the Plan to the contrary, and other than pursuant to
Section 13, the Compensation Committee shall not without the approval of the Company’s stockholders (a) lower the Exercise Price per Share of an Option (or grant price of a SAR) after it is granted, (b) cancel an Option or SAR in exchange for
an Option or SAR with a lower Exercise Price, cash or another Grant (other than in connection with a Change in Control), or (c) take any other action with respect to an Option or SAR that would be treated as a repricing under the rules and
regulations of the principal U.S. national securities exchange on which the Shares are listed. 
 (c) Stockholder Re-Approval
Requirement. If Stock Awards, Stock Units, Cash-Based Awards, Other Stock-Based Awards or Dividend Equivalents are granted as “qualified performance-based compensation” under Section 11 above, the Plan must be reapproved by the
stockholders no later than the first stockholders meeting that occurs in the fifth year following the year in which the stockholders previously approved the provisions of Section 11, if required by Code section 162(m) or the regulations thereunder.

 (d) Termination of Plan. The Plan shall terminate on December 3, 2024, unless the Plan is terminated earlier by the Board or is
extended by the Board with the approval of the stockholders; provided, however, in no event may an ISO be granted more than ten years after the date of the adoption of the Plan by the Board. 

(e) Termination and Amendment of Outstanding Grants. A termination or amendment of the Plan that occurs after a Grant is made shall not
materially impair the rights of a Grantee unless the Grantee consents or unless the Compensation Committee acts under Section 17(f) above. The termination of the Plan shall not impair the power and authority of the Compensation Committee with
respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 17(f) above or may be amended by agreement of the Company and the Grantee consistent with the Plan. 

(f) Prior Plan. Any Grants made under the Plan prior to the Restatement Effective Date shall be governed by the terms of the Plan in
effect at the time each such Grant was made, unless further amended in accordance with the terms of the Grant and such version of the Plan. For the avoidance of doubt, any Grants made under the Plan on or after the Restatement Effective Date, shall
be subject to the terms of the Plan in effect on and after the Restatement Effective Date. 

  
 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]